Skip to content

Bacterial Targeting and Manipulation of Tumour Cell Metabolism

Abstract

The tumour-trophic Salmonella enterica serovar Typhimurium strain SL7207 has previously been demonstrated to successfully deliver shRNA targeting the oncogene c-Myc in murine models (Williams et al., 2024). This project extends the utility of SL7207 as a bacterial delivery platform for therapeutic RNA interference, focusing on metabolic reprogramming of cancer cells through the knockdown of lactic acid transporters (MCT1, MCT4) and key glycolytic enzymes (LDHA, LDHB). Bacterial strains modified to enhance bacterial utilisation of lactic acid did not outperform wild-type SL7207, highlighting the bacterium’s intrinsic ability to adapt to low-pH, lactic acid-rich environments. Confocal microscopy and qPCR analyses showed that bacterial cell division genes such as ftsI-2 are upregulated under these conditions in the presence of eukaryotic cells demonstrating the genetic adaptations SL7207 employs to thrive. SL7207 strains were engineered to deliver shRNA targeting key metabolic genes, enabling investigation of the resulting impact on cancer cell viability and phenotype. Although early knockdown of MCT1 and MCT4 was observed via qPCR and western blotting, expression rebounded, likely due to compensatory induction of HIF-1α and c-Myc pathways, which were found to upregulate MCT4 and MCT1, respectively. To enhance delivery, a stable high-copy plasmid (pLF301) was developed, achieving improved knockdown of LDHA and LDHB. This knockdown led to rapid cancer cell death, a loss of migratory potential, and prevention of cell senescence in breast and colon cancer models. Transcriptomic profiling of infected cells revealed a progression from immediate immune signalling and regulatory shifts to transcriptional recovery and chromatin remodelling over 24 hours post-infection. These results highlight SL7207’s potential as a modular tool for metabolic interference in tumours and lay the groundwork for further development of multiplexed shRNA delivery and immunometabolic investigation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.